E. François

发表

Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).

A. Lièvre, M. Ychou, J. Taïeb, 2020, Clinical colorectal cancer.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

T. Conroy, P. Laurent-Puig, M. Ychou, 2014, British Journal of Cancer.

Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.

M. Ychou, A. Abad, M. Marty, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC

B. Chauffert, J. Pignon, T. Conroy, 2013, European journal of cancer.

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

M. Ychou, M. Stern, F. Bidard, 2019, Cells.

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Bernard Leduc, Franck Bonnetain, Olivier Bouché, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

T. Conroy, S. Gourgou-Bourgade, M. Jarlier, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Aims of combined modality therapy in rectal cancer (M0).

J. Gérard, K. Bénézery, E. François, 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Management and clinical outcome of rectal cancer in patients ≥80 years treated in southern France (PACA region) between 2006 and 2008

X. Hébuterne, L. Mineur, E. Chamorey, 2013, Journal of surgical oncology.

Clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2002 and 2005

J. Gérard, O. Guerin, J. Gal, 2012, Strahlentherapie und Onkologie.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

T. Conroy, Y. Bécouarn, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of response in rectal cancer: we are still far from the "crystal ball".

J. Gérard, E. François, 2010, Digestive and Liver Disease.

State of the art and recent advance in the treatment of resectable nonmetastatic rectal cancer.

J. Gérard, K. Bénézery, E. François, 2007, Surgical oncology.

Update on neoadjuvant strategies for rectal cancer patients

J. Gérard, E. François, 2007 .

Docetaxel chronopharmacology in mice.

P. Vrignaud, F. Lévi, E. Filipski, 1998, Cancer research.

[Population study of dihydropyrimidine dehydrogenase in cancer patients].

O. Dassonville, F. Demard, G. Milano, 1994, Bulletin du cancer.

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

T. Conroy, M. Ychou, E. Assenat, 2018, Journal of Clinical Oncology.

The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown

M. Ychou, E. Assenat, D. Smith, 2021, medRxiv.

Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020.

A. Lièvre, P. Ries, M. Gilabert, 2020, Journal of geriatric oncology.

KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications

I. Soubeyran, A. Italiano, Y. Bécouarn, 2010, Annals of Surgical Oncology.

Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

A. Italiano, F. Caroli-Bosc, J. Gugenheim, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

T. Conroy, Y. Bécouarn, O. Bouché, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

M. Ychou, J. Douillard, F. Goldwasser, 2012, Clinical colorectal cancer.

Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study).

B. Chauffert, T. Conroy, M. Ychou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients.

S. Marcié, J. Gugenheim, J. Gérard, 2017, European journal of cancer.

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

P. Rougier, O. Bouché, A. de Gramont, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.

T. Conroy, M. Ychou, M. Ducreux, 2005, European journal of cancer.

Dose-finding study of weekly 24h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients

P. Hérait, G. Deplanque, J. Bereder, 2004 .

Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.

P. Hérait, G. Deplanque, J. Bereder, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Palliative 5-Fluorouracil-Based Chemotherapy for Advanced Colorectal Cancer in the Elderly: Results of a 10-Year Experience

M. Namer, J. Ferrero, Alain Ramaïoli, 2002, American journal of clinical oncology.

PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.

F. Retornaz, J. Seitz, T. André, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Role of Radiotherapy With Surgery for T3 and Resectable T4 Rectal Cancer: Evidence From Randomized Trials

J. Bosset, D. Benchimol, O. Thomas, 2006, Diseases of the colon and rectum.

Sphincter and rectal preservation approaches for early stage distal rectal cancers

P. Marcy, J. Gérard, E. François, 2006 .

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.

J. Douillard, G. Milano, M. Etienne-Grimaldi, 2012, British journal of clinical pharmacology.

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Christophe Hennequin, Bernard Denis, Pierre-Luc Etienne, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACCORD12/0405-Prodige 2 Phase III Trial Neoadjuvant Treatment in Rectal Cancer: Results after 3 Years of Follow-up

T. Conroy, P. Romestaing, S. Gourgou-Bourgade, 2011 .

Rectal Cancer: Rectal Preservation Is an Important End Point

G. Milano, J. Gérard, G. Freyer, 2010 .

Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG).

A. Bouvier, G. Albrand, E. Paillaud, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

C. Lepage, O. Bouché, C. Pétorin, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.

B. Chauffert, M. Ychou, M. Ducreux, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

B. Chauffert, T. Conroy, M. Ducreux, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of raltitrexed ('Tomudex') in patients with hepatocellular carcinoma.

D. Kerr, M. Ducreux, P. Rougier, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer

T. Conroy, M. Ychou, M. Ducreux, 2008, British Journal of Cancer.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

C. Borel, C. Lepage, V. Boige, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Clinical Pharmacokinetic Analysis of Tegafur-Uracil (UFT) Plus Leucovorin Given in a New Twice-Daily Oral Administration Schedule

J. Douillard, G. Milano, J. Cardot, 2007, Clinical pharmacokinetics.

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

D. Kerr, E. Van Cutsem, D. Cunningham, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation

G. Milano, J. Ferrero, E. François, 2004, British Journal of Cancer.

M. Namer, G. Milano, J. Ferrero, 1996, Clinical pharmacology and therapeutics.

K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy

P. Laurent-Puig, C. Létoublon, G. Milano, 2008, Clinical Cancer Research.

Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.

C. Létoublon, J. Formento, G. Milano, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan?

G. Poissonnet, P. Marcy, O. Dassonville, 2004, Cancer.

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial

T. Conroy, M. Déjardin, J. Bosset, 2004 .

Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study.

R. Schiappa, J. Gugenheim, J. Gérard, 2019, European journal of cancer.

ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group.

I. Seymour, E. Van Cutsem, J. Zalcberg, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control

C. Mariette, G. Piessen, A. Kramar, 2016, Oncology.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

O. Bouché, F. Retornaz, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).

T. Conroy, G. Deplanque, C. Borg, 2016 .

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

A. Monnier, P. Fumoleau, E. Pujade-Lauraine, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

O. Bouché, F. Retornaz, J. Taieb, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology)

M. Ychou, J. Duffour, M. Ducreux, 2008 .

VINORELBINE IN EPIDERMOID ESOPHAGEAL

T. Conroy, M. Glabbeke, J. Seitz, 2018 .

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

L. Quéro, C. Maritaz, C. Borg, 2022, Frontiers in Oncology.

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Sung-Bae Kim, M. Shah, F. Lordick, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

T. Conroy, C. Borg, V. Boige, 2020, Journal of Clinical Oncology.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients

D. Arsène, C. Lepage, G. Deplanque, 2015, PloS one.

A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial

M. Ychou, M. Ducreux, C. Létoublon, 2013, Annals of Surgical Oncology.

Cisplatin Nephrotoxicity: A Multivariate Analysis of Potential Predisposing Factors

X. Pivot, G. Milano, J. Ferrero, 1997, Pharmacotherapy.

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.

M. Ychou, E. Assenat, Y. Bécouarn, 2016 .

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial.

T. Conroy, J. Bosset, O. Bouché, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of oxaliplatin (Eloxatine®, LOHP) to the same leucovorin (LV) and 5 fluorouracil (5FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary report

O. Bouché, A. Gramont, T. André, 1997 .

Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensified chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (LMCRC). (METHEP)

M. Ychou, M. Ducreux, R. Guimbaud, 2008 .

Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study.

T. Conroy, M. Ychou, M. Ducreux, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cetuximab (CTX) in first-line treatment of elderly patients with metastatic colorectal cancer (mCRC), KRAS wild type: French multicentre prospective community-based registry and results.

R. Guimbaud, L. Mineur, E. François, 2017 .

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

C. Borg, B. Buecher, O. Bouché, 2018, The Lancet. Oncology.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial

A. Vincent-Salomon, I. Bièche, F. Bidard, 2018, Clinical Cancer Research.

Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).

M. Ychou, J. Duffour, M. Ducreux, 2006, Anticancer research.

Outcomes of surgical management for borderline (BR)/locally advanced (LA) pancreatic adenocarcinoma (PAC) after neoadjuvant FOLFIRINOX chemotherapy: Results of an AGEO/French multicenter study.

J. Vaillant, J. Blanc, R. Coriat, 2014 .

Chronopharmacokinetics of Oral Tegafur and Uracil in Colorectal Cancer Patients

J. Douillard, G. Milano, J. Cardot, 2008, Clinical pharmacology and therapeutics.

Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Failure of Initial Curative Treatment for Non-Metastatic Anal Squamous Cell Carcinoma: From Prognostic Factors Analysis to Stratified Treatment.

R. Schiappa, K. Bénézery, E. François, 2022, Clinical colorectal cancer.

Pharmacokinetics of weekly low dose doxorubicin.

M. Namer, G. Milano, A. Thyss, 1989, European journal of cancer & clinical oncology.

Metastatic Hepatic Epithelioid Hemangio-Endothelioma: Long-Term Response to Sunitinib Malate

J. Gugenheim, P. Follana, E. François, 2014, Oncology Research and Treatment.

Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study.

J. Pignon, T. Conroy, M. Ducreux, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.

C. Borel, V. Boige, O. Bouché, 2016 .

Salivary passage of 5-fluorouracil during continuous infusion

F. Demard, J. Santini, G. Milano, 2004, Cancer Chemotherapy and Pharmacology.

Cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cell lines characterized for EGFR expression and K-ras mutation.

G. Milano, M. Etienne-Grimaldi, J. Fischel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of age on chemoradiotherapy outcome in patients with rectal cancer: Exploratory analysis from the phase III study ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of a multiparametric approach.

C. Borg, J. Metges, E. Gamelin, 2013 .

Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion.

G. Milano, J. Lagrange, A. Thyss, 1993, Journal of the National Cancer Institute.

DPD status and fluoropyrimidines-based treatment: high activity matters too

R. Schiappa, A. Bozec, G. Milano, 2020, BMC Cancer.

Preoperative Chemoradiotherapy (CT-RT) Improves Local Control in T3-4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial

T. Conroy, O. Bouché, P. Romestaing, 2005 .

Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib

N. Magné, F. Demard, X. Pivot, 2003 .

Primary tumour staging of gastric and colorectal cancer

C. Raffaelli, B. Padovani, J. Bruneton, 2004, European Radiology.

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

J. Taïeb, S. Olschwang, V. Boige, 2022, Therapeutic advances in medical oncology.

Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud – Nice experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients

S. Marcié, P. Romestaing, J. Gérard, 2015, Acta oncologica.

A prospective study of pancreatic disease in patients with alcoholic cirrhosis: comparative diagnostic value of ERCP and EUS and long-term significance of isolated parenchymal abnormalities.

F. Caroli-Bosc, M. Buckley, J. Delmont, 1999, Gastrointestinal endoscopy.

Recommendations for bowel obstruction with peritoneal carcinomatosis.

V. Servois, F. Guirimand, L. Copel, 2014, Journal of pain and symptom management.

[Chemoradiotherapy and anal canal cancer].

J. Gérard, E. François, C. Ortholan, 2005, Bulletin du cancer.

[Preneoplastic anal lesions and anal canal carcinoma].

J. Gérard, E. François, C. Ortholan, 2003, Bulletin du cancer.

Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study).

D. Cowen, N. Salem, J. Gérard, 2012, International journal of radiation oncology, biology, physics.

High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study).

D. Cowen, N. Salem, J. Gérard, 2011, International journal of radiation oncology, biology, physics.

Controlled transperitoneal percutaneous cecostomy as a therapeutic alternative to the endoscopic decompression for Ogilvie's syndrome.

P. Marcy, P. Chevallier, B. Padovani, 2002 .

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Lecomte, Sophie Gourgou, T. Conroy, 2018, The New England journal of medicine.

Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy

P. Bondiau, J. Gérard, A. Naghavi, 2017, Clinical colorectal cancer.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

M. Ducreux, A. Cazes, C. Borg, 2017, European journal of cancer.

Contact X-ray therapy for rectal cancer: experience in Centre Antoine-Lacassagne, Nice, 2002-2006.

J. Gérard, K. Bénézery, E. Chamorey, 2008, International journal of radiation oncology, biology, physics.

SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.

L. Zelek, Thierry Nguyen, S. Bisot-Locard, 2012, Bulletin du cancer.

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors for Which FISH Analysis Does Not Detect an Increase in EGFR Gene Copy Number

A. Italiano, J. Gugenheim, P. Follana, 2008, Annals of Surgical Oncology.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

T. Conroy, G. Deplanque, J. Metges, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controlled transperitoneal percutaneous cecostomy as a therapeutic alternative to the endoscopic decompression for Ogilvie's syndrome

P. Marcy, P. Chevallier, B. Padovani, 2002, American Journal of Gastroenterology.

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

F. Carbonnel, J. Blanc, J. Taieb, 2014, Annals of Surgical Oncology.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Phase I Trial of Gemcitabine Combined with Capecitabine and Erlotinib in Advanced Pancreatic Cancer: A Clinical and Pharmacological Study

J. Douillard, G. Milano, P. Follana, 2012, Chemotherapy.

Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.

M. Namer, G. Milano, A. Thyss, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T. Conroy, C. Borg, O. Bouché, 2021, Clinical colorectal cancer.

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

T. Conroy, C. Borel, G. Deplanque, 2019, JAMA oncology.

Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients.

A. Lièvre, W. Cacheux, R. Guimbaud, 2019, The oncologist.

Effectiveness of first‐line cetuximab in wild‐type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort

A. Fourrier-Réglat, N. Moore, E. Bignon, 2020, British journal of clinical pharmacology.

Commentary

P. Follana, J. Gérard, E. François, 2008 .

Clinical response assessment after contact X-Ray brachytherapy and chemoradiotherapy for organ preservation in rectal cancer T2-T3 M0: The time/dose factor influence

R. Schiappa, J. Gérard, K. Bénézery, 2020, Clinical and translational radiation oncology.

Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal

K. Bénézery, E. François, A. Falk, 2019, Cancer medicine.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

P. Laurent-Puig, F. Penault-Llorca, C. Borg, 2019, European journal of cancer.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

C. Reinhold, C. Borel, C. Lepage, 2019, Gut.

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

M. Ychou, E. Assenat, R. Guimbaud, 2022, British Journal of Cancer.

Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort

J. Taieb, R. Coriat, J. Bachet, 2021, British Journal of Cancer.

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.

B. Esterni, P. Viens, R. Largillier, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.

P. Rougier, J. Douillard, A. de Gramont, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor assay: Validation of a single point method and application to breast cancer

M. Namer, G. Milano, J. Fischel, 2005, Breast Cancer Research and Treatment.

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

T. Conroy, J. Douillard, V. Boige, 2014, The Lancet. Oncology.

DPD status and fluoropyrimidines-based treatment: high activity matters too

R. Schiappa, A. Bozec, G. Milano, 2020, BMC Cancer.

Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.

L. Quéro, A. Lièvre, C. Lepage, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

High-l-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer : Final results of a phase l i study ,

T. Conroy, M. Ducreux, D. Peiffert, 2005 .

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

E. Tartour, F. Penault-Llorca, N. Radosevic-Robin, 2019, Gastric Cancer.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

T. Conroy, J. Bosset, C. Borg, 2021, The Lancet. Oncology.

VINORELBINE IN EPIDERMOID ESOPHAGEAL CARCINOMA 167

T. Conroy, J. Seitz, A. Adenis, 2017 .

VINORELBINE IN EPIDERMOID ESOPHAGEAL CARCINOMA

E. François, H. Bleiberg, B. Paillot, 2017 .

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.

M. van Glabbeke, T. Conroy, M. Glabbeke, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

O. Bouché, A. de Gramont, T. André, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials

C. Borg, B. Buecher, D. Vernerey, 2020, International journal of molecular sciences.

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.

B. Esterni, P. Viens, R. Largillier, 2012 .

Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.

T. Gorlia, T. Conroy, E. Van Cutsem, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).

T. Conroy, P. Laurent-Puig, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study

P. Follana, J. Seitz, E. Chamorey, 2012, Journal of chemotherapy.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

C. Borg, J. Metges, E. Gamelin, 2017, Seminars in oncology.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study

E. Chamorey, V. Mari, E. François, 2008, Cancer Chemotherapy and Pharmacology.

Results of age-dependent anal canal cancer treatment: a single centre retrospective study.

P. Follana, J. Gérard, K. Bénézery, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers

S. Msika, T. Conroy, M. Copin, 2018, BMC Cancer.

Preoperative endosonographic staging of cancer of the cardia

J. Mouroux, J. Simon, E. François, 1996, Abdominal Imaging.

GUIDED GERIATRIC INTERVENTIONS (GI) AND NUTRITIONAL STATUS: A STUDY FROM THE PACA EST FRENCH COHORT

S. Gonfrier, X. Hébuterne, O. Guerin, 2019, Journal of Geriatric Oncology.

Laval assessing octreotide LAR in inoperable bowel obstruction

L. Zelek, Thierry Nguyen, S. Bisot-Locard, 2012 .

Predictive Factors for Early and Late Local Toxicities in Anal Cancer Treated by Radiotherapy in Combination With or Without Chemotherapy

P. Follana, J. Gérard, K. Bénézery, 2013, Diseases of the colon and rectum.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP).

M. Ducreux, C. Borg, D. Peiffert, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Interstitial high-dose rate brachytherapy as boost for anal canal cancer

J. Gérard, K. Bénézery, J. Hannoun-levi, 2014, Radiation oncology.

Reply to R. Glynne-Jones et al.

T. Conroy, M. Ducreux, D. Peiffert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study.

T. Conroy, M. Ducreux, D. Peiffert, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab: A dose review.

P. Follana, E. François, A. Falk, 2015, Critical reviews in oncology/hematology.

Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.

N. Magné, V. Boige, B. De Bari, 2022, European journal of cancer.

Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide.

C. Balu-Maestro, P. Cambon, J. Riess, 1989, Radiology.

NACRE: A randomized study comparing short course radiotherapy with radiochemotherapy for locally advanced rectal cancers in the elderly—Preliminary results.

N. Magné, V. Boige, E. François, 2021 .

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).

T. Conroy, C. Mariette, G. Piessen, 2019, European journal of cancer.

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

M. Ychou, E. Assenat, O. Bouché, 2021, Annals of Oncology.

Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer

J. Douillard, H. Naman, P. Piedbois, 2007, British Journal of Cancer.

FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

C. Borg, O. Bouché, F. Ghiringhelli, 2015 .

PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer

R. Guimbaud, P. Soulié, L. Mineur, 2020, PloS one.

Influence of the comprehensive geriatric assessment (CGA) in elderly metastatic cancer patients. Analysis from a prospective cohort of 1048 patients.

G. Poissonnet, S. Gonfrier, E. Benizri, 2016 .

Concurrent concentrated chemoradiation therapy in squamous cell carcinoma of the esophagus: long term results of a national multicenter phase II study in 122 inoperable patients (FFCD 8803)

T. Conroy, J. Seitz, F. Dumas, 2000 .

Assessment of “squamous cell carcinoma antigen” (SCC) as a marker of epidermoid carcinoma of the anal canal

M. Namer, P. Chauvel, J. Lagrange, 1991, Diseases of the colon and rectum.

Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients

E. Tartour, F. Ghiringhelli, J. Taieb, 2021, Cancers.

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

C. Borg, B. Buecher, O. Bouché, 2020, Therapeutic advances in medical oncology.

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up.

T. Conroy, O. Bouché, S. Gourgou-Bourgade, 2016 .

Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience

P. Follana, K. Bénézery, E. François, 2017, Diseases of the colon and rectum.

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database

T. Petit, M. Mouret-Reynier, F. Joly, 2021, Breast.

P h ase I I T rial o f Vinorelbine i n M e tastatic Squam o us C ell E sophageal C arcinoma

T. Conroy, J. Seitz, A. Adenis, 1996 .

Predicting early death in older adults with cancer.

G. Poissonnet, S. Gonfrier, T. Piche, 2018, European journal of cancer.

Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal

J. Gérard, K. Bénézery, J. Hannoun-levi, 2018, Journal of contemporary brachytherapy.

Interstitial high-dose rate brachytherapy as boost for anal canal cancer

J. Gérard, K. Bénézery, J. Hannoun-levi, 2014, Radiation Oncology.

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

M. Ychou, E. Assenat, D. Botsen, 2021, JAMA network open.

[Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma].

M. Namer, X. Pivot, J. Ferrero, 1995, Bulletin du Cancer.

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

T. Conroy, M. Ychou, J. Douillard, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of bevacizumab in elderly patients with metastatic colorectal cancer: Review

P. Follana, V. Mari, O. Guerin, 2011 .

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

M. Ducreux, F. Lévi, M. Marty, 2001, British Journal of Cancer.

Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.

M. Ducreux, F. Lévi, M. Marty, 2000, European journal of cancer.

SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer.

A. Lièvre, P. Laurent-Puig, C. Lepage, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The Desire to Better Understand Older Adults with Solid Tumors to Improve Management: Assessment and Guided Interventions—The French PACA EST Cohort Experience

S. Gonfrier, P. Hofman, O. Guerin, 2019, Cancers.

Phase II trial with ifosfamide in pancreatic cancer.

N. Duez, E. François, J. Wils, 1993, European Journal of Cancer.

Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach

G. Deplanque, J. Gagnière, F. Fein, 2017, Therapeutic drug monitoring.

Prognostic value of total cathepsin D in breast tumors

M. Héry, A. Ramaioli, M. Namer, 1991, Breast Cancer Research and Treatment.

Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.

M. Ducreux, P. Soulié, M. Marty, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[Pathogenesis and management of refractory malignant ascites].

P. Follana, F. Peyrade, V. Mari, 2011, Bulletin du Cancer.

A Phase II Trial of Raltitrexed (Tomudex®) in Advanced Pancreatic and Biliary Carcinoma

H. Bourgeois, J. Douillard, M. Hebbar, 2005, Oncology.

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Clinical Relevance of Viable Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer: The COLOSPOT Prospective Study

M. Ychou, J. Daurès, E. Assenat, 2021, Cancers.

FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort

J. Taieb, R. Coriat, J. Bachet, 2019, Annals of Oncology.

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

C. Lepage, C. Pétorin, J. Seitz, 2018 .

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma

Sung-Bae Kim, C. Borg, B. Buecher, 2019, Annals of Oncology.

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.

G. Milano, M. Etienne-Grimaldi, E. François, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Effectiveness of Cetuximab as First‐Line Therapy for Patients With Wild‐Type KRAS and Unresectable Metastatic Colorectal Cancer in Real‐Life Practice: Results of the EREBUS Cohort

A. Fourrier-Réglat, N. Moore, R. Lassalle, 2018, Clinical colorectal cancer.

Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse.

P. Bondiau, A. Naghavi, K. Bénézery, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.

G. Batist, T. Shore, F. Porzsolt, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study.

G. Deplanque, Stefano Kim, L. Mineur, 2020, Clinical colorectal cancer.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

W. Cacheux, M. Ychou, M. Stern, 2016 .

Value of urinary hydroxyproline and bone isoenzyme of alkaline phosphatase in the early detection and follow-up of bone metastasis in breast cancer patients.

M. Namer, G. Milano, M. Frénay, 1988, Bulletin du cancer.

Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

S. Olschwang, V. Boige, O. Bouché, 2016 .

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study.

E. Van Cutsem, T. Price, J. Seitz, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy.

A. Monnier, P. Fumoleau, N. Colombo, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.

V. Boige, O. Bouché, L. Mineur, 2021, Journal of Clinical Oncology.

[Neoadjuvant approach for non-metastatic rectal cancer combining radiotherapy and chemotherapy. Biotargeted drugs].

G. Milano, J. Gérard, K. Bénézery, 2009, Bulletin du Cancer.

[Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)].

T. Conroy, J. Seitz, F. Dumas, 2000, Gastroenterologie clinique et biologique.

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

M. Ychou, E. Assenat, Y. Bécouarn, 2018 .

[Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].

C. Lombard-Bohas, P. Niccoli, B. Vergès, 2014, Bulletin du cancer.

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

V. Boige, O. Bouché, F. Ghiringhelli, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

1297P Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial

T. Conroy, J. Iovanna, J. Biagi, 2022, Annals of Oncology.

Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX

P. Follana, J. Gal, E. François, 2015, Oncology.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

M. Ducreux, A. Cazes, C. Borg, 2017, European journal of cancer.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2009, Journal of Clinical Oncology.

Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.

N. Magné, F. Demard, X. Pivot, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[Pathogenesis and management of refractory malignant ascites].

P. Follana, V. Mari, F. Peyrade, 2011, Bulletin du cancer.

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study).

D. Cowen, N. Salem, J. Gérard, 2011, International journal of radiation oncology, biology, physics.

Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.

B. Chauffert, T. Conroy, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRODIGE 2 phase III trial neoadjuvant in rectal cancer: Quality of life and results at 5 years.

T. Conroy, P. Rouanet, O. Bouché, 2016 .

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

E. Tartour, F. Penault-Llorca, N. Radosevic-Robin, 2019, Gastric Cancer.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients

D. Arsène, C. Lepage, G. Deplanque, 2015, PloS one.

477OBevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

T. Conroy, G. Deplanque, C. Borg, 2017 .

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)--A randomized phase II trial.

O. Bouché, F. Retornaz, J. Taieb, 2015 .

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial.

T. Conroy, J. Bosset, O. Bouché, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.